ORPHA:90037
Drug-induced autoimmune hemolytic anemia
Also known as: Drug-induced AIHA
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Clinical definition (Orphanet)
Drug-induced autoimmune hemolytic anemia is a type of autoimmune hemolytic anemia (AIHA) that occurs as a reaction to therapeutic drugs, and can be due to various mechanisms.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Is anyone studying this?
103
103 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
103 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
64 in the last 10 years · high confidence · 60.9th percentile (publications denominator)
Is a treatment being tested?
0
trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 72 trials are registered for autoimmune hemolytic anemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 26 July 2026
72
trials for autoimmune hemolytic anemia, the broader category this belongs to
Trials registered for a broader category may or may not enrol people with this specific subtype — eligibility criteria vary, and the trial record often doesn't say. Worth raising with a clinician. How we count trials.
No matched interventional trials. This is true for 59.2% of diseases in the trials denominator (151 of 255). Here are the researchers publishing on it.
high confidence · 29.6th percentile (trials denominator)
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Who's working on it?
503
Distinct author names in 103 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Barcellini W5 papers · 2024
U.O. Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 02Fattizzo B3 papers · 2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, 20100 Milan, Italy.
Papers in Europe PMC - 03Michel M3 papers · 2019
Department of Medicine, Henri Mondor Hospital, Université Paris-Est, Assistance Publique Hôpitaux de Paris Creteil, Creteil, France.
Papers in Europe PMC - 04
- 05Berentsen S2 papers · 2024
Department of Research and Innovation, Haugesund Hospital, P.O. Box 2170, Haugesund, 5504, Norway.
Papers in Europe PMC - 06Hadid T2 papers · 2020
Van Elslander Cancer Center, 19229 Mack Ave, Suite 23, Grosse Pointe Woods, MI 48236 USA.
Papers in Europe PMC - 07Ito K2 papers · 2026
Dept. of Pediatric Nephrology, Tokyo Women's Medical College.
Papers in Europe PMC - 08Mitrović M2 papers · 2023
Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.
Papers in Europe PMC - 09Shen Y2 papers · 2021
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Papers in Europe PMC - 10Sugimoto T2 papers · 2026
Department of Dermatology, Nippon Medical School Musashikosugi Hospital.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
72 interventional trials matched autoimmune hemolytic anemia, the broader category — see the summary above. Those studies are not counted in the condition-specific total.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Drug-induced autoimmune hemolytic anemia" OR "Drug-induced AIHA"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Drug-induced autoimmune hemolytic anemia" OR "Drug-induced AIHA" OR "autoimmune disorder of blood"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Cross-references (from Mondo): UMLS:C0391817
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus